Want to see RPRX full AI Analyst Report?
RPRX Stock Chart & Stats
$58.83
-$0.19(-0.32%)
At close: 4:00 PM EDT
$58.83
-$0.19(-0.32%)
Day’s Range― - ―
52-Week Range$34.08 - $60.44
Previous CloseN/A
Volume2.11M
Average Volume (3M)3.18M
Market Cap
$34.19B
Enterprise Value$42.30K
Total Cash (Recent Filing)$836.99M
Total Debt (Recent Filing)$8.96B
Price to Earnings (P/E)24.7
Beta0.17
Next Earnings
Nov 11, 2026EPS Estimate
1.17Next Dividend Ex-DateN/A
Dividend Yield1.55%
Share Statistics
EPS (TTM)2.41
Shares Outstanding445,277,340
10 Day Avg. Volume2,718,135
30 Day Avg. Volume3,176,121
Financial Highlights & Ratios
PEG Ratio0.78
Price to Book (P/B)2.58
Price to Sales (P/S)7.02
P/FCF Ratio6.70
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$65.67Price Target Upside11.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)5.31
Revenue Forecast (FY)$3.49B
Bulls Say, Bears Say
Bulls Say
Strong Recurring Cash GenerationRoyalty receipts convert efficiently into cash, with operating cash flow well above net income and free cash flow growth reaccelerating. This provides durable funding for debt service, acquisitions and shareholder returns while supporting resilience across product cycles.
Growing Royalty Receipts And Raised GuidanceThe upgraded outlook and double-digit recurring receipt growth indicate continued expansion in the underlying royalty portfolio. Because these contractual cash flows can persist over product lives, growth may remain more durable than event-driven milestone income.
Pipeline Expansion And Active Capital DeploymentA larger development-stage portfolio broadens future royalty opportunities and can replenish assets as mature products face competition. Active deployment also demonstrates sourcing capability and creates potential for long-term portfolio compounding, subject to clinical success.
Bears Say
Meaningful And Rising LeverageThe debt burden reduces financial flexibility if royalty receipts weaken or acquisition returns disappoint. Although strong cash generation and investment-grade access provide support, continued leverage requires disciplined capital allocation and dependable portfolio performance.
Product Exclusivity And Policy HeadwindsLoss of exclusivity, biosimilar competition and pricing-policy changes can reduce royalty receipts from important underlying products. These pressures may persist across multiple periods and require replacement growth from newer assets and acquisitions.
Clinical Risk In Development-stage InvestmentsDevelopment-stage royalties offer substantial upside but do not yet provide dependable cash flows. Failed trials, delays or weaker commercial outcomes could impair expected returns and leave capital tied up longer, making portfolio expansion inherently exposed to clinical uncertainty.
Royalty Pharma News
RPRX FAQ
What was Royalty Pharma PLC’s price range in the past 12 months?
Royalty Pharma PLC lowest stock price was $34.08 and its highest was $60.44 in the past 12 months.
What is Royalty Pharma PLC’s market cap?
Royalty Pharma PLC’s market cap is $34.19B.
When is Royalty Pharma PLC’s upcoming earnings report date?
Royalty Pharma PLC’s upcoming earnings report date is Nov 11, 2026 which is in 83 days.
How were Royalty Pharma PLC’s earnings last quarter?
Royalty Pharma PLC released its earnings results on Aug 05, 2026. The company reported $1.321 earnings per share for the quarter, beating the consensus estimate of $1.273 by $0.048.
Is Royalty Pharma PLC overvalued?
According to Wall Street analysts Royalty Pharma PLC’s price is currently Undervalued.
Does Royalty Pharma PLC pay dividends?
Royalty Pharma PLC pays a Quarterly dividend of $0.235 which represents an annual dividend yield of 1.55%. See more information on Royalty Pharma PLC dividends here
What is Royalty Pharma PLC’s EPS estimate?
Royalty Pharma PLC’s EPS estimate is 1.17.
How many shares outstanding does Royalty Pharma PLC have?
Royalty Pharma PLC has 445,277,340 shares outstanding.
What happened to Royalty Pharma PLC’s price movement after its last earnings report?
Royalty Pharma PLC reported an EPS of $1.321 in its last earnings report, beating expectations of $1.273. Following the earnings report the stock price went up 0.47%.
Which hedge fund is a major shareholder of Royalty Pharma PLC?
Currently, no hedge funds are holding shares in RPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Royalty Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$65.67 (11.62% Upside)
$65.67 (11.62% Upside)
Blogger Sentiment
Neutral
RPRX Sentiment 60%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 469.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
64.23%
12-Months-Change
Fundamentals
Return on Equity
1.55%
Trailing 12-Months
Asset Growth
8.17%
Trailing 12-Months
Company Description
Royalty Pharma PLC
Royalty Pharma plc (RPRX) is a biopharmaceutical royalty company that acquires and manages a portfolio of royalty and related interests in revenue-generating biopharmaceutical products and late-stage development programs. The company operates in the life sciences/healthcare sector and provides capital to drug developers (including biopharmaceutical companies, academic institutions, hospitals, and research organizations) in exchange for future cash flows tied to product sales, milestones, or other drug-related payments.
RPRX Company Deck
RPRX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized multiple strong positives: double‑digit recurring cash flow growth, raised full‑year guidance, disciplined capital deployment (including a strategic cliramitug purchase), expanded development‑stage pipeline with high historical success rates, robust cash generation, and an investment‑grade credit upgrade. Lowlights were present but largely manageable: a material decline in milestone/contract receipts (one‑time prior period effect), specific product headwinds (Promacta, biosimilar Tysabri, IRA), dependence on future pivotal trial outcomes for some investments, modestly higher expected operating expense rates in H2, and geopolitical/regulatory uncertainty in China. Overall, the positives—strong growth, improved guidance, financial flexibility, and portfolio expansion—substantially outweigh the risks and near‑term headwinds.View all RPRX earnings summariesRPRX Revenue Breakdown
93.34% Income from financial royalty assets
6.62% Other royalty income
0.04% Revenue from intangible royalty assets
RPRX Stock 12 Month Forecast
Average Price Target
$65.67
▲(11.62% Upside)
Technical Analysis
Ownership Overview
1.52% Insiders
19.23% Mutual Funds
25.90% Other Institutional Investors
42.28% Public Companies and
Individual Investors